Related Experiment Videos
Emergent operation for percutaneous coronary rupture after abciximab administration
1Division of Cardiothoracic Surgery, University of North Carolina School of Medicine, Chapel Hill 27599-7065, USA. charless@med.unc.edu
The Annals of Thoracic Surgery
|June 28, 2001
Summary
Coronary artery rupture during angioplasty, especially with abciximab, poses risks. Emergency surgery following this complication, even with abciximab, can lead to significant postoperative bleeding.
Area of Science:
- Cardiovascular medicine
- Interventional cardiology
- Pharmacology
Background:
- Percutaneous coronary intervention (PCI) is a common treatment for coronary artery disease.
- Abciximab is an antiplatelet medication used during PCI to prevent thrombotic complications.
- Coronary artery perforation is a rare but serious complication of PCI.
Observation:
- A 72-year-old woman experienced coronary artery rupture during angioplasty while on abciximab therapy.
- Standard treatment of prolonged balloon reinflation was unsuccessful in sealing the perforation.
- Emergency coronary artery ligation and bypass surgery were performed.
Findings:
- The patient developed excessive postoperative bleeding following the emergency surgical intervention.
- Abciximab administration complicated the management of coronary artery perforation and subsequent surgery.
- The combination of coronary artery rupture and abciximab therapy presented significant hemostatic challenges.
Implications:
- This case highlights the potential for severe bleeding complications when managing coronary artery perforation in patients treated with abciximab.
- Careful consideration of antiplatelet therapy and surgical hemostasis is crucial in such high-risk scenarios.
- Further research may be needed to optimize management strategies for coronary artery perforation during abciximab therapy.